Newsmeme!
Discover News you didn't know existed
(ARA) - For people with heart and breathing conditions--and their caregivers--it can be difficult to determine if the body is getting enough oxygen.
Today • 10 a.m. to noon – Field trip to Finsch’s Autumn Fest, 301 W. Johnson St., Palatine. Special outing for small children includes a crazy corn maze, spooky forest trail, hay bale play and more. Admission: $6 a child ages 1-12. Host: The Parent Connection. Registration and information: 815-425-3766 or e-mail: parent.connection@yahoo.com.
Title: Health Tip: Coping With COPD Category: Health News Created: 10/10/2008 2:00:00 AM Last Editorial Review: 10/10/2008
Title: FDA Rethinks Spiriva Stroke Warning Category: Health News Created: 10/10/2008 Last Editorial Review: 10/10/2008
Better Breathers Support Group, 2 p.m. Baxter Regional Center on Aging, 618 Broadmoor Drive. For those with emphysema, bronchitis, asthma, chronic obstructive pulmonary disease and other breathing problems. 508-1569.
Based on positive Phase II trial findings, Bayer Schering Pharma will move into Phase III trials with its oral agent riociguat (BAY 63-2521). Riociguat is the first member of a new class of vasodilating agents called soluble guanylate cyclase (sGC) stimulators. It is being investigated as a new approach for the treatment of different forms of pulmonary hypertension.
Results of the UPLIFT® trial, presented at the European Respiratory Society (ERS) Annual Congress, demonstrated that tiotropium (Spiriva®) administered to Chronic Obstructive Pulmonary Disease (COPD) patients, showed sustained improvements in lung function for up to 4 years (pAbout COPD C
Nicotine dependence is the physical vulnerability to the chemical nicotine, which is potently addicting when delivered by various tobacco products. Smoke from cigarettes, cigars and pipes contains thousands of chemicals, including nicotine. Being addicted to tobacco brings a host of health problems related to the substances in tobacco smoke. These effects include damage to the lungs, heart ...
(RTTNews) - Glenmark Pharmaceuticals Ltd., a research-driven integrated pharmaceutical company, said it has initiated Phase II study for its lead molecule Oglemilast - GRC 3886 - for the treatment of asthma.
Glenmark Pharmaceuticals Ltd (India) [Glenmark] has announced that a phase-II study for its lead molecule Oglemilast (GRC 3886) for the treatment of asthma has been initiated.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |